Study to Evaluate D2 Receptor Occupancy Following Single Intravenous Administration of ATI-9242
NCT02824666
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
7
Enrollment
INDUSTRY
Sponsor class
Conditions
Schizophrenia
Interventions
DRUG:
ATI-9242
RADIATION:
[18F]Fallypride Imaging
Sponsor
Braeburn Pharmaceuticals